Palo Alto Investors LP Purchases Shares of 62,587 United Therapeutics Corporation $UTHR

Palo Alto Investors LP acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 62,587 shares of the biotechnology company’s stock, valued at approximately $33,911,514,000. United Therapeutics makes up 4.7% of Palo Alto Investors LP’s portfolio, making the stock its 8th largest position. Palo Alto Investors LP owned about 0.15% of United Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in UTHR. Torren Management LLC bought a new stake in United Therapeutics during the 4th quarter valued at approximately $26,000. Fiduciary Financial Advisors purchased a new position in United Therapeutics in the 2nd quarter worth approximately $30,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares in the last quarter. Entrust Financial LLC bought a new position in United Therapeutics in the 4th quarter worth approximately $31,000. Finally, Caitlin John LLC bought a new position in United Therapeutics in the 2nd quarter worth approximately $37,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, JPMorgan Chase & Co. boosted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $646.00.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total transaction of $4,914,160.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $167,827,875.04. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,631,280.08. This trade represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 424,075 shares of company stock worth $227,336,485 in the last 90 days. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $527.91 on Friday. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35. The business has a 50 day simple moving average of $530.89 and a two-hundred day simple moving average of $538.86. The stock has a market capitalization of $22.64 billion, a PE ratio of 18.89, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm earned $6.41 EPS. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.